Table 3.
Reasons for ineligibility of 102 patients based on pathological review report
| Pathology variables | Cohort (n = 102) |
NL cohort (n = 42) |
UK cohort (n = 60) |
|||
|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |
| Histological type | 35 | 34 | 14 | 33 | 21 | 35 |
| Histologic gradea | 19 | 19 | 7 | 17 | 12 | 20 |
| Myometrial invasion | 7 | 7 | 3 | 7 | 4 | 7 |
| Cervical involvement | 27 | 27 | 12 | 29 | 15 | 25 |
| LVSI | 4 | 4 | 2 | 5 | 2 | 3 |
| Otherb | 10 | 10 | 4 | 10 | 6 | 10 |
| Total ineligible patients | 102 | 100 | 42 | 100 | 60 | 100 |
| Percentage of total cohort | 102 | 8 | 42 | 11 | 60 | 7 |
a
Grade shift for endometrioid endometrial carcinoma.
b
Other reasons included the absence of involvement of the ovaries, tube or parametrium, or other primary tumour site (cervix, tube or adnex).
LVSI, lymph vascular space invasion; NL, Netherlands; UK, United Kingdom.